-
If you purchased shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) and currently hold any of those NASDAQ:VTAE shares, you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
September 16, 2016 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE), was announced concerning whether the takeover of Vitae Pharmaceuticals Inc by Allergan plc is unfair to NASDAQ:VTAE stockholders.
The investigation by a law firm concerns whether certain officers and directors of Vitae Pharmaceuticals Inc breached their fiduciary duties owed to NASDAQ:VTAE investors in connection with the proposed acquisition.
On September 14, 2016, Allergan plc (NYSE:AGN) and Vitae Pharmaceuticals Inc (NASDAQ:VTAE) announced that they have entered into an agreement under which Allergan will acquire Vitae Pharmaceuticals Inc (NASDAQ:VTAE) for $21.00 per share, in cash, for a total transaction value of approximately $639 million.
However, the investigation concerns whether the offer is unfair to NASDAQ:VTAE stockholders. More specifically, the investigation concerns whether the Vitae Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) reached in December 2014 as high as $22.01 per share,
